The end of the beginning of personalized medicine

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2695-2695

  Natoli, G ^a   Capalbo, C ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DRUG;

CANCER SURVIVAL; DRUG APPROVAL; DRUG MARKETING; DRUG RESEARCH; DRUG TARGETING; FISHER EXACT TEST; HEALTH CARE; HUMAN; LETTER; PATENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; SURVIVAL RATE; TREATMENT RESPONSE; VALIDATION PROCESS;

EID: 82355191826     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr430     Document Type: Letter

References (3)

1. Soria JC, Blay JY, Spano JP et al. Added value of molecular targeted agents in oncology. Ann Oncol 2011; 22: 1717-1725.
2. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011; 364: 1087-1089.
3. Aspinall MG, Hamermesh G. Realizing the promise of personalized medicine. Harv Bus Rev 2007; 10: 108-117.